JAMA
EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, FEBRUARY 26, 2019
Media advisory: To contact corresponding author Kevin L. Nelson, Ph.D., email Lynn Closway at Closway.Lynn@mayo.edu. The full study is linked to this news release.
Want to embed a link to this study in your story? This full-text link will be live at the embargo time: https://jamanetwork.com/journals/jama/fullarticle/2725673?guestAccessKey=d1c4b9d2-5808-487c-a3ca-a6dd4d530da9&utm_source=JAMA Network&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=022619
Bottom Line: Radioactive compounds known as radiopharmaceuticals are used in nuclear medicine procedures to diagnose and treat disease. This research letter reports on radiation contamination at an Arizona crematorium where a man with a pancreatic tumor was cremated after treatment with an intravenous radioactive drug. A later examination of the crematorium found evidence of radiation contamination on equipment, including the oven, vacuum filter and bone crusher. A trace amount of a different type of radioactive compound not used in the man with the pancreatic tumor was also detected in the crematory operator’s urine, suggesting he may have been possibly exposed to that compound while cremating other human remains. Regulations for cremating patients treated with radiopharmaceuticals vary by state and internationally. More studies are needed to evaluate the extent of radiation contamination at crematoriums and the potential health effects of exposure for crematorium employees, especially with a cremation rate greater than 50 percent in the United States in 2017.
Authors: Nathan Y. Yu, M.D., Mayo Clinic, Phoenix, Arizona, and coauthors.
(doi:10.1001/jama.2018.21673)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.